David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Huntington Ingalls Industries
HII
$11.4B
| $14.2M | 0.02% |
68,606
+46,469
| +210% | +$9.53M |
|
|
ENDP
877
DELISTED
Endo International plc
ENDP
| $14.2M | 0.02% |
1,764,691
-1,575,875
| -47% | -$14.8M |
|
878
GameStop
GME
$8.1B
| $14.1M | 0.02% |
5,556,972
+4,794,308
| +629% | +$14.9M |
|
879
CALL
Paycom
PAYC
$10.4B
| $14.1M | 0.02% |
74,600
+18,900
| +34% | +$3.07M |
|
880
Mercury Systems
MRCY
$5.24B
| $14.1M | 0.02% |
220,056
+57,316
| +35% | +$3.3M |
|
881
iRhythm Holdings
IRTC
$4.13B
| $14.1M | 0.02% |
187,552
+106,380
| +131% | +$9.09M |
|
882
Neurocrine Biosciences
NBIX
$15.6B
| $14M | 0.02% |
159,284
-51,239
| -24% | -$4.28M |
|
883
Designer Brands
DBI
$286M
| $14M | 0.02% |
631,459
+383,957
| +155% | +$10.1M |
|
|
QUOT
884
DELISTED
Quotient Technology Inc
QUOT
| $14M | 0.02% |
1,414,974
+230,584
| +19% | +$2.37M |
|
885
CALL
Lam Research
LRCX
$392B
| $13.9M | 0.02% |
776,000
-350,000
| -31% | -$5.84M |
|
886
PUT
Bausch Health
BHC
$2.43B
| $13.8M | 0.02% |
560,000
-1,010,000
| -64% | -$24.1M |
|
887
Sibanye-Stillwater
SBSW
$8.76B
| $13.8M | 0.02% |
3,337,459
| – | – |
|
888
Cimpress
CMPR
$2.11B
| $13.7M | 0.02% |
170,960
-134,006
| -44% | -$12.2M |
|
889
Jack Henry & Associates
JKHY
$12.2B
| $13.6M | 0.02% |
98,363
+30,990
| +46% | +$4.1M |
|
|
AGN
890
CALL
DELISTED
Allergan plc
AGN
| $13.6M | 0.02% |
93,100
-2,700
| -3% | -$391K |
|
891
Wingstop
WING
$3.13B
| $13.6M | 0.02% |
179,117
+130,617
| +269% | +$8.9M |
|
|
FOLD
892
DELISTED
Amicus Therapeutics
FOLD
| $13.6M | 0.02% |
1,000,626
+109,646
| +12% | +$1.34M |
|
893
CALL
LendingTree
TREE
$432M
| $13.6M | 0.02% |
+38,600
| New | +$11.7M |
|
894
Brixmor Property Group
BRX
$9.04B
| $13.6M | 0.02% |
738,421
-998,716
| -57% | -$17M |
|
895
Lincoln National
LNC
$8.11B
| $13.5M | 0.02% |
230,674
+177,581
| +334% | +$10.5M |
|
|
MXIM
896
DELISTED
Maxim Integrated Products
MXIM
| $13.5M | 0.02% |
254,549
-200,724
| -44% | -$10.8M |
|
|
ADSW
897
DELISTED
Advanced Disposal Services Inc
ADSW
| $13.5M | 0.02% |
482,477
+33,059
| +7% | +$860K |
|
898
Varex Imaging
VREX
$781M
| $13.5M | 0.02% |
398,610
-57,964
| -13% | -$1.75M |
|
899
PUT
Costco
COST
$428B
| $13.4M | 0.02% |
55,500
-328,300
| -86% | -$71.8M |
|
900
Tactile Systems Technology
TCMD
$539M
| $13.4M | 0.02% |
253,979
+229,514
| +938% | +$14.8M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.